Moderna has announced the publication of interim data for mRNA-3927, a therapy for propionic acidemia, in Nature. The phase 1/2 study marks the first clinical data using mRNA therapy for intracellular protein. Preliminary findings suggest potential clinical benefits for propionic acidemia patients.
Nature research paper: Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia https://t.co/RNQ0MeiBVV
Moderna Reports Phase I/II Data for Propionic Acidemia mRNA Therapy These preliminary findings are encouraging and suggest that Moderna's mRNA-3927 may have clinical benefits for propionic acidemia patients. Learn more: https://t.co/IyxY2v59sW
#FlagshipFounded @moderna_tx announces the publication of interim data in @Nature for a first-in-human, phase 1/2 study of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA). https://t.co/tSlgfLFeoZ
"Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia" https://t.co/wejx10x2MA
Today, we announced that interim data for a first-in-human, phase 1/2 study of mRNA-3927, an investigational #mRNA #therapy for propionic acidemia (PA), has been published in Nature. This is the first published clinical data utilizing mRNA therapy for intracellular protein… https://t.co/7sAD4mnVdV